Preview

river blindness

Satisfactory Essays
Open Document
Open Document
614 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
river blindness
1. The stakeholders are any party that is affected by the business and its actions .In this situation the stakeholders are the customers, employees, suppliers, the government, stockholders, and the community. In this case the most important stakeholders are the customers and the community.
2. I t would take about 12 years and 200 million dollars for research and development. This drug would benefit the people who are affected by river blindness. I believe many pharmaceutical in the area that river blindness occurs will invest in the cure for river blindness.
3. However, Merck could not justify such an investment in terms of financial at all, because this development is a big financial risk. Merck works for a company that is committed to the people, so they take risk to better the people. This is the main reason they would create a cure for river blindness
4. Merck could tell them that the cost to develop a cure for river blindness would be too high and the investment would be too risky due to the decline in the percentage of sales. That if they attempt to create a cure it will cause the company to go under. If he decided not to create a cure his employees should understand, because he is trying to do what is best for the company and his employees.
5. The media would show Merck Company that is not about making a fortune, that they are all about helping people and saving life. If he decided not to create a cure for river blindness, the media would show the company as a selfish and cold heart company that only care about how much money they can generate. If he decided to create a cure people probably buy more of his product and he would attract brilliant scientists. If he decided not to create a cure people probably would buy less of his products and less scientists would want to come to his company.
6.
7. Merck value system plays a very important role in making a decision whether to create a cure for river blindness. His decision will affect how the public

You May Also Find These Documents Helpful

  • Satisfactory Essays

    Scm421merckcasereport 2

    • 790 Words
    • 3 Pages

    Phase One: The KL-798 product has been under testing phases for six months. Based on Kappa Labs’ project team research there is a 60% chance of Phase One successful completion. If Merck were to buy the product rights, the cost incurred to complete this would be $5 million.…

    • 790 Words
    • 3 Pages
    Satisfactory Essays
  • Powerful Essays

    The purpose of this paper is to research, analyze and whether to recommend Merck & Co. to potential investors. I will be using both qualitative and quantitative analysis based on previous years of data for the company. I will provide efficient background information (life cycle analysis) including a brief history of Merck & Co., it’s stock chart since being added to the market, any advantages or disadvantages it has within its industry and important news that may affect a potential investor’s willingness to buy or sell this stock.…

    • 1517 Words
    • 7 Pages
    Powerful Essays
  • Satisfactory Essays

    First, note that the $170 million spent are sunk costs, they will be lost regardless of the decision. The relevant question is whether the incremental benefits (the present value of the profits generated from the drug) exceed the incremental costs (the $30 million needed to keep the project alive). Since these costs and benefits span time, it is appropriate to compute the net present value. Here, the net present value of DAS’s R&D initiative is $26,557,759.86…

    • 6653 Words
    • 39 Pages
    Satisfactory Essays
  • Powerful Essays

    Merck & Co. Inc. is one of the world’s largest pharmaceutical companies in the world for producers of prescription drugs. Merck had sales of 1.98 billion and net income of 307 million in 1978 and continues to steadily rise. Merck invested hundreds of millions of dollars each year in research and allocate the funds amongst various projects. On average it would take approximately 12 years and 200 million dollars to bring a new drug into the market. Many potential drugs offered little chance of financial returns, as some diseases were so rare that treatment could never be priced high enough for the company to recoup the investment. Congress sought to encourage drug companies to further research on rare diseases by proposing tax benefits and seven-year exclusive marketing rights if they manufactured drugs for diseases afflicting fewer than 200,000 Americans. River blindness, also known as “onchocerciasis” is a disease found in over 35 developing countries throughout the Third World. The cause of the disease came from parasitic worm that were carried by black flies. In 1978, the World Health Organization (WHO) estimated that approximately 340,000 people were blind because of this disease and 18 million or more were infected with the parasite, but not many showed symptoms. Merck researchers have found a compound called ‘Ivermectin’, which has proven to have an astonishing effect against wide range of parasites in animals. Dr. Campbell proposed the idea to have the compound formulated to work against human parasite, but the success rate was very low. Even if the drug was successful attained, the economy viability would be nil and no U.S. or international program would create any incentives for Merck to develop drugs for diseases like river blindness.…

    • 829 Words
    • 3 Pages
    Powerful Essays
  • Satisfactory Essays

    Gm 533 Statistics

    • 284 Words
    • 2 Pages

    The company management has decided to market this product if the expected contribution to profit for the next six months is more than $90,000. Based on the information given above, should the company begin manufacturing the new drug?…

    • 284 Words
    • 2 Pages
    Satisfactory Essays
  • Better Essays

    Merck Kl798 Case

    • 920 Words
    • 4 Pages

    Based on the decision tree model, it is recommended that Pat Harlow does not invest in the purchase of KL-798 from Kappa Labs assuming that the current payoffs and expected probabilities given currently are correct and do not change in the future. At the current decision point, during Phase I tests, there is an expected payoff of -$1.16 million based on the probabilities of success further in the future and expected returns. If Merck can negotiate either the price of KL-798 down by more than $1.16 million or reduce their contribution to complete Phase I testing, this could be an attractive option to invest in.…

    • 920 Words
    • 4 Pages
    Better Essays
  • Good Essays

    Merck Decision Tree

    • 456 Words
    • 2 Pages

    Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Merck's highest priority areas are Alzheimer’s disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines, obesity, oncology, pain and sleep disorders. In addition, and importantly for licensing, the following other areas remain of high interest for focused investment in new compounds and mechanisms: antibiotics, antifungals, antivirals (HCV and HIV), asthma, COPD, neurodegeneration, ophthalmology, osteoporosis, schizophrenia, and stroke.…

    • 456 Words
    • 2 Pages
    Good Essays
  • Satisfactory Essays

    Drug Companies and Ethics

    • 656 Words
    • 3 Pages

    Merck is one of the largest and most profitable drug companies in the world, but they have also been a leader in a donation program that helps Third World countries in Africa, South America and Yemen since the 1980’s.…

    • 656 Words
    • 3 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Biopure Case

    • 196 Words
    • 1 Page

    In regard to this topic, among all of the case studies assigned by Dr. Mena, the case about Biopure Corp stood out as a significant example of overestimating some aspects of the strategic planning that led to the failure of the business. Biopure Corp had spent million of dollars on research and development to create two versions of blood substitute for human and animal called Hemopure and Oxyglobin. During the strategic planning process, Biopure was optimistic with both Hemopure and Oxyglobin because of Oxyglobin high acceptance rate among the consumers for a market research survey and it was already approved for release by the FDA. However, the company made a fatal mistake of underestimating the government regulation and strategic uncertainty…

    • 196 Words
    • 1 Page
    Satisfactory Essays
  • Better Essays

    Merck & Co

    • 1066 Words
    • 5 Pages

    Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999, and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research, and (2) developing partnerships with smaller biotechnology companies. Since 1995, Merck had launched 15 new products that earned $5.9 billion on sales of $32.7 billion. Furthermore, Merck may agree to license new drugs from other firms and with its larger capital and greater assets, can assume the risk of submitting the drug through various regulatory approval phases. If the drug becomes profitable, Merck can earn significant cash flows while paying a royalty to the licensor. However, most important is the option that Merck has in deciding when to abandon or continue on this project (deferability or optionality). If Merck reaches a point when its expected NPV is negative, it can simply abandon the project.…

    • 1066 Words
    • 5 Pages
    Better Essays
  • Powerful Essays

    Merck River Blindness

    • 1355 Words
    • 6 Pages

    Introduction and Situational Analysis Merck and River Blindness ethical dilemma is whether to pursue research that may or may affect the profits, or to choose a safer choice and go for profit rather than researching the drug. The outcome from researching the drug could possibly lead to healing the deadly and dangerous disease known as River Blindness. This drug is known to kill the parasite that has caused the disease. The problem with this situation was that the consumers of the drug could not pay for the medication. Therefore would result in no profit for Merck’s company.…

    • 1355 Words
    • 6 Pages
    Powerful Essays
  • Good Essays

    Merck considered this opportunity as a high risk investment. The cost of developing the drug was estimated at $100 million. Even if it was successful to cure river blindness the victims were too poor to afford the drug. There was no way to distribute it in these rural areas were the victims were located. In addition, there was a possibility that people would misuse the drugs, which would cause negative side effects and stimulate bad press for Merck. During this time, healthcare costs were on the rise, Medicare and Medicaid reimbursements were limited for companies developing drugs like Merck. Congress was also about to pass an act that would make it easier for competitors to copy and market generic drugs. All of this opposition made Merck hesitant about developing Ivermectin.…

    • 686 Words
    • 2 Pages
    Good Essays
  • Good Essays

    Merck Case

    • 587 Words
    • 4 Pages

    Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999, and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research, and (2) developing partnerships with smaller biotechnology companies. Since 1995, Merck had launched 15 new products that earned $5.9 billion on sales of $32.7 billion. Furthermore, Merck may agree to license new drugs from other firms and with its larger capital and greater assets, can assume the risk of submitting the drug through various regulatory approval phases. If the drug becomes profitable, Merck can earn significant cash flows while paying a royalty to the licensor. However, most important is the option that Merck has in deciding when to abandon or continue on this project (deferability or optionality). If Merck reaches a point when its expected NPV is negative, it can simply abandon the project. As a licensee, Merck can allow smaller biotechnology firms to focus on research and development. These smaller firms often have smaller budgets and are not financially or personnel equipped to handle the costly and long FDA approval process, and the subsequent marketing, distribution, and sales of new drugs. This task is better suited for a larger company, such as Merck, which has more resources and money.…

    • 587 Words
    • 4 Pages
    Good Essays
  • Good Essays

    Inc., a large pharmaceutical product and service company. The dilemma arose in the 1970s when a potential breakthrough was discovered for river blindness. They had developed and produced a drug for animals named Invermectin. It was discovered that this drug could also cure river blindness however a safe and effective human version would have to be created. The costs were then weighed and the person who stood to benefit from the drugs would not be able to afford it even if was sold at cost. Producing the drug on the other hand would be a scientific breakthrough for the pharmaceutical industry and lead to further development of drugs for other diseases. Merck then had to decide if they should abandon the drug altogether as it would be a financial loss or produce it and eliminate the disease and relieve tormented victims. It should be noted that either option chosen would be classified as ethical. There was no law that required Merck to produce the drug although societal backlash would be a consequent. However, choosing the alternative of financing the drug would cause disapproval from…

    • 990 Words
    • 4 Pages
    Good Essays